BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Treatment
16 results:

  • 1. Tumor Necrosis Factor-
    Chen X; Lin L; Wu Q; Li S; Wang H; Sun Y
    Mediators Inflamm; 2023; 2023():5679966. PubMed ID: 37124061
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Fabrication of polymer-based self-assembly nanocarriers loaded with a crizotinib and gemcitabine: potential therapeutics for the treatment of endometrial cancer.
    Yang J; Guo H; Lei J; Zhang S; Zhang S; Bai J; Li S
    J Biomater Sci Polym Ed; 2022 Jan; 33(1):20-34. PubMed ID: 34602004
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Serous endometrial intraepithelial carcinoma (SEIC): Current clinical practice in The Netherlands.
    Slaager C; Hofhuis W; Hoogduin K; Ewing-Graham P; van Beekhuizen H
    Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():25-29. PubMed ID: 34416579
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect.
    Kras P; Talkowski K; Grabarek BO; Skalska-Dziobek N; Boroń D; Oplawski M
    Curr Pharm Biotechnol; 2021; 22(5):697-705. PubMed ID: 32648839
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Self-assembled dihydroartemisinin nanoparticles as a platform for cervical cancer chemotherapy.
    Lu Y; Wen Q; Luo J; Xiong K; Wu Z; Wang B; Chen Y; Yang B; Fu S
    Drug Deliv; 2020 Dec; 27(1):876-887. PubMed ID: 32516033
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Endometrial cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
    Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
    Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Inkjet printing of antiviral pcl nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration.
    Varan C; Wickström H; Sandler N; Aktaş Y; Bilensoy E
    Int J Pharm; 2017 Oct; 531(2):701-713. PubMed ID: 28432016
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A study of the synergistic effect of folate-decorated polymeric micelles incorporating Hydroxycamptothecin with radiotherapy on xenografted human cervical carcinoma.
    You H; Fu S; Qin X; Yu Y; Yang B; Zhang G; Sun X; Feng Y; Chen Y; Wu J
    Colloids Surf B Biointerfaces; 2016 Apr; 140():150-160. PubMed ID: 26752212
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Porphine functionalized nanoparticles of star-shaped poly(ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 1000 succinate biodegradable copolymer for chemophotodynamic therapy on cervical cancer.
    Cao W; Zeng X; Liu G; Li Z; Zeng X; Wang L; Huang L; Feng SS; Mei L
    Acta Biomater; 2015 Oct; 26():145-58. PubMed ID: 26283167
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combination of IL-24 and cisplatin inhibits angiogenesis and lymphangiogenesis of cervical cancer xenografts in a nude mouse model by inhibiting VEGF, VEGF-C and PDGF-B.
    Wang Z; Lv J; Zhang T
    Oncol Rep; 2015 May; 33(5):2468-76. PubMed ID: 25778843
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein.
    Liu J; Cheng Y; He M; Yao S
    Gynecol Endocrinol; 2014 Jun; 30(6):461-5. PubMed ID: 24650367
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
    Collinson F; Hutchinson M; Craven RA; Cairns DA; Zougman A; Wind TC; Gahir N; Messenger MP; Jackson S; Thompson D; Adusei C; Ledermann JA; Hall G; Jayson GC; Selby PJ; Banks RE
    Clin Cancer Res; 2013 Sep; 19(18):5227-39. PubMed ID: 23935036
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Patterns of cervical cancer screening, diagnosis, and follow-up treatment in a state Medicaid fee-for-service population.
    Nadpara PA; Madhavan SS; Khanna R; Smith M; Miller LA
    Popul Health Manag; 2012 Dec; 15(6):362-71. PubMed ID: 22788858
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Recovery issues of fertility-preserving surgery in patients with early-stage cervical cancer and a model for survivorship: the physician checklist.
    Carter J; Raviv L; Sonoda Y; Chi DS; Abu-Rustum NR
    Int J Gynecol Cancer; 2011 Jan; 21(1):106-16. PubMed ID: 21178573
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Fracasso PM; Blessing JA; Wolf J; Rocereto TF; Berek JS; Waggoner S
    Gynecol Oncol; 2003 Jul; 90(1):177-80. PubMed ID: 12821360
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.